RCKT - ROCKET PHARMACEUTICALS, INC.

QQQ $ 444.77 $ -0.81 (-0.18 %)

DIA $ 392.27 $ -0.25 (-0.06 %)

SPY $ 527.69 $ -0.10 (-0.02 %)

TLT $ 96.30 $ 0.26 (0.27 %)

GLD $ 221.35 $ -0.66 (-0.3 %)

Previous Close

$ 20.13

Open

$ 20.15

Bid

$ 19.47 x 100

Ask

$ 19.50 x 101

Day's Range

$ 19.48 - $ 20.15

52 Week Range

$ 14.89 - $ 32.53

Volume

1,001,124

Average Volume

Market Cap

1.89B

Beta (5Y Monthly)

$ 1.26

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	02-27-2024	12-31-2023	10-K
4	11-07-2023	09-30-2023	10-Q
5	08-09-2023	06-30-2023	10-Q
6	05-05-2023	03-31-2023	10-Q
7	02-28-2023	12-31-2022	10-K
8	11-04-2022	09-30-2022	10-Q
9	08-09-2022	06-30-2022	10-Q
10	05-06-2022	03-31-2022	10-Q
11	02-28-2022	12-31-2021	10-K
12	11-05-2021	09-30-2021	10-Q
13	08-09-2021	06-30-2021	10-Q
14	05-10-2021	03-31-2021	10-Q
15	03-01-2021	12-31-2020	10-K
16	11-06-2020	09-30-2020	10-Q
17	08-05-2020	06-30-2020	10-Q
18	05-08-2020	03-31-2020	10-Q
19	03-06-2020	12-31-2019	10-K
20	11-08-2019	09-30-2019	10-Q
21	08-08-2019	06-30-2019	10-Q
22	05-09-2019	03-31-2019	10-Q
23	03-08-2019	12-31-2018	10-K
24	11-09-2018	09-30-2018	10-Q
25	08-14-2018	06-30-2018	10-Q
26	05-11-2018	03-31-2018	10-Q
27	03-07-2018	12-31-2017	10-K
28	11-08-2017	09-30-2017	10-Q
29	08-03-2017	06-30-2017	10-Q
30	05-10-2017	03-31-2017	10-Q
31	03-16-2017	12-31-2016	10-K
32	11-09-2016	09-30-2016	10-Q
33	08-10-2016	06-30-2016	10-Q
34	05-11-2016	03-31-2016	10-Q
35	03-23-2016	12-31-2015	10-K
36	11-12-2015	09-30-2015	10-Q
37	08-07-2015	06-30-2015	10-Q
38	05-14-2015	03-31-2015	10-Q
39	03-31-2015	12-31-2014	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

JP Morgan Maintains Overweight on Rocket P...
08/06/2024 16:05:42

JP Morgan analyst Eric Joseph maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and raises the price target f...

Cantor Fitzgerald Reiterates Overweight on...
08/06/2024 15:20:43

Cantor Fitzgerald analyst Josh Schimmer reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and maintains $65 ...

Chardan Capital Maintains Buy on Rocket Ph...
08/06/2024 11:34:11

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $62 price ta...

Needham Reiterates Buy on Rocket Pharmaceu...
08/06/2024 10:14:51

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $52 price target.

Rocket Pharmaceuticals Q2 EPS $(0.74) Miss...
08/05/2024 20:15:32

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate...

Canaccord Genuity Maintains Buy on Rocket ...
07/03/2024 14:21:39

Canaccord Genuity analyst Whitney Ijem maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target...

Chardan Capital Maintains Buy on Rocket Ph...
06/28/2024 19:05:55

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $62 price ta...

Needham Maintains Buy on Rocket Pharmaceut...
06/28/2024 14:51:01

Needham analyst Gil Blum maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $53 to $52.

fda-rejects-rocket-pharmaceuticals-gene-therapy-for-rare-immune-disorder-asks-for-more-data-stock-slides

FDA Rejects Rocket Pharmaceuticals' Gene T...
06/28/2024 13:52:06

Rocket Pharmaceuticals shares fell after the FDA issued a Complete Response Letter for Kresladi, a gene therapy for severe leuk...

nike-accolade-and-other-big-stocks-moving-lower-in-fridays-pre-market-session

Nike, Accolade And Other Big Stocks Moving...
06/28/2024 13:08:43

Trading Halt: Halt status updated at 7:55:...
06/28/2024 11:55:05

The FDA Issued Complete Response Letter To...
06/28/2024 11:31:33

Trading Halt: Halted at 6:56:37 a.m. ET - ...
06/28/2024 10:56:41

European Commission Has Granted Orphan Med...
05/29/2024 11:16:54

Rocket Pharmaceuticals Presents Longer-Ter...
05/10/2024 10:04:07

Long-term KRESLADI follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplanta...

Needham Reiterates Buy on Rocket Pharmaceu...
05/07/2024 11:17:18

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.

Rocket Pharmaceuticals Q1 EPS $(0.66) Beat...
05/06/2024 20:03:12

Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate o...

Needham Reiterates Buy on Rocket Pharmaceu...
04/10/2024 10:08:21

Needham analyst Gil Blum reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $53 price target.

Goldman Sachs Initiates Coverage On Rocket...
04/02/2024 11:07:21

Goldman Sachs analyst Richard Law initiates coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) with a Neutral rating and annou...

The European Medicines Agency Accepted The...
04/02/2024 10:04:04